Internal tandem duplication mutations of the FLT3 gene (FLT3-ITD) are commonly acquired mutations in acute myeloid leukemia (AML) and are associated with a high risk of relapse. The FLT3 inhibitor sorafenib has been evaluated in FLT3-mutated AML postallogeneic stem cell transplantation (alloSCT).
| CASE
Internal tandem duplication mutations of the FLT3 gene (FLT3-ITD) are commonly acquired mutations in acute myeloid leukemia (AML) and are associated with a high risk of relapse. The FLT3 inhibitor sorafenib has been evaluated in FLT3-mutated AML postallogeneic stem cell transplantation (alloSCT).
1
A 60-year-old man diagnosed with FLT3-ITD-positive AML in second remission underwent a sibling donor alloSCT. On Day +59, an extensive papular rash developed on his lower back, thought most likely to represent acute Graft-VersusHost disease. However, skin biopsy demonstrated an infiltrate of myeloblasts consistent with leukemia cutis ( Figure 1A and 1B) that was FLT3-ITD mutation positive. On Day +71, he started sorafenib monotherapy (400 mg BD) resulting in a substantial clinical improvement after two weeks (Figure 2A and 2B). A donor lymphocyte infusion was administered on Day + 122 for bone marrow relapse resulting in a remission of several months until he relapsed and died on Day + 505. Sorafenib for relapsed FLT3-ITD-positive AML presenting as leukemia cutis has rarely been described. 2 This case highlights the need to consider leukemia cutis in the differential diagnosis of a rash early post-alloSCT and the rapidity of the response that can be achieved with sorafenib. 
